Structure based GPCR drug discovery

Tue2  Sep11:00am(30 mins)
Charter 1


Despite significant effort spanning many decades traditional screening approaches such as high-throughput screening have failed to fully unlock the potential of the GPCR superfamily and new, complementary approaches to GPCR drug discovery are required.
Heptares have tackled this challenge developing an integrated drug discovery platform around a unique ability, using stabilised receptor (StaRĀ®) technology, to stabilise receptors in precisely defined biologically-relevant conformations. StaRsĀ® are amenable to a number of techniques that cannot be readily used with wild-type GPCRs, including biophysical and biochemical fragment screening, kinetic profiling using surface-plasmon resonance (SPR), crystallographic studies and Biophysical Mapping. Structure-based drug discovery is now a reality for this family, and the impact of new structures for GPCR drug discovery will be discussed.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021